Jack Allen
Stock Analyst at Baird
(0.57)
Main Sectors:
Top Industries:
Name | Action | PT | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
VOR Vor Biopharma | Maintains: Neutral | 1 1 | 1.99 | -49.75% | 4 | Jun 27, 2025 | |
FATE Fate Therapeutics | Maintains: Neutral | 5 4 | 0.94 | 325.53% | 2 | May 14, 2025 | |
ALLO Allogene Therapeutic... | Maintains: Outperform | 12 9 | 1.03 | 773.79% | 3 | May 14, 2025 | |
CARM CARISMA Therapeutics | Downgrades: Neutral | 10 1 | n/a | n/a | 3 | Dec 12, 2024 | |
INKT MiNK Therapeutics | Maintains: Outperform | 80 40 | 12.23 | 227.06% | 2 | Nov 15, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 77 106 | 69.11 | 53.38% | 5 | Nov 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 24 18 | 10.75 | 67.44% | 2 | Oct 25, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 180 180 | 28.28 | 536.49% | 9 | Sep 16, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 140 120 | 4.97 | 2314.49% | 3 | Aug 15, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 8 | 1.51 | 429.8% | 1 | Jun 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 46 52 | 55.44 | -6.2% | 2 | May 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 84 | 31.9 | 163.32% | 1 | Oct 31, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 200 25 | n/a | n/a | 3 | Sep 26, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 6 8 | 2.75 | 190.91% | 4 | Aug 15, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 21 6 | 4.91 | 6.92% | 2 | Aug 10, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 5 | 1 | 400% | 1 | Nov 2, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 9 | 3.2 | 181.25% | 1 | Sep 13, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 2 | May 18, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 6 9 | 3.08 | 192.21% | 1 | Oct 7, 2021 |